One company is aiming to treat infections with a different strategy: arming tiny viruses called bacteriophages with Crispr. Known as phages for short, these viruses naturally infect and kill bacteria.
The power of CRISPR became definitively clear when the first CRISPR-based gene therapy, Casgevy (exa-cel), won regulatory approvals for the treatment of sickle cell disease. But CRISPR’s ...
If you love investing in stocks you're bound to buy some losers. Long term CRISPR Therapeutics AG (NASDAQ:CRSP) shareholders know that all too well, since the share price is down considerably over ...